LifeSciences BC > News > Member Announcements > Page 2

ARTMS appoints interim CEO and two new Board members to focus on growth and global commercialization

April 4, 2018
Quark Venture Inc.

Vancouver, Canada, March 28, 2018 –(BUSINESSWIRE)– Having recently obtained a significant seed investment from Quark Venture Inc. through the Global Health Sciences Fund, ARTMS Products Inc. today announced the appointment of Dr. Kaley Wilson, PhD, as the interim Chief Executive Officer. To continue to solidify the company’s technology and prepare it for global commercialization, founder and … Continue reading ARTMS appoints interim CEO and two new Board members to focus on growth and global commercialization

Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P.

April 2, 2018
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, March 28, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today reported the closing of the previously announced transaction with Teva Pharmaceuticals International GmbH, along with Teva Canada Limited (collectively, “Teva”), to terminate by mutual agreement the collaborative development and license agreement dated December 7, 2012, as amended. … Continue reading Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P.

Celebrating Life Science Innovators Noted as BC Women of Influence

March 23, 2018
LifeSciences BC

VANCOUVER, BC – March 23, 2018, The BC LifeSciences Association is pleased to celebrate the following women in Life Sciences in BC Businesses 2018 Women of Influence list. The list celebrates top female influencers making an impact in science, technology, engineering and math (STEM): Louise Turner – CEO, Innovation Boulevard, partnership between City of Surrey … Continue reading Celebrating Life Science Innovators Noted as BC Women of Influence

Aequus Expands Market in Quebec for Tacrolimus IR

March 19, 2018
Aequus Pharmaceuticals Inc.

First-to-market generic tacrolimus will be included on Sigma Santé contract as of May 2018, building on continued commercial success of Aequus’ promotional arm VANCOUVER, BC. March 19, 2018 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announced today that it has been awarded a three-year contract with Sigma Santé for its … Continue reading Aequus Expands Market in Quebec for Tacrolimus IR

Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer

March 16, 2018
Xenon Pharmaceuticals Inc.

Changes to Senior Leadership Support Expanding Neurology Pipeline BURNABY, British Columbia, March 13, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Ernesto Aycardi will join the company as its Chief Medical Officer (CMO) providing leadership and execution of Xenon’s clinical development programs, including its two clinical stage … Continue reading Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer

Arbutus Announces Corporate Update and Year-End 2017 Financial Results

March 14, 2018
Arbutus Biopharma Corporation

ARB-1467 Phase II Combination Study Beginning in 1Q18 Two New Drug Candidates Planned to Enter Clinical Development in 2H18 Over $200M in CashAvailable to Fund Development of HBV Assets Company to Host a Corporate Update Conference Call Today at 4:30 PM ET VANCOUVER, British Columbia and WARMINSTER, Pa., March 14, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation(Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today … Continue reading Arbutus Announces Corporate Update and Year-End 2017 Financial Results

Arbutus Announces Conference Call to Provide a Corporate Update and Fourth Quarter 2017 Year-End Financial Results

March 12, 2018
Arbutus Biopharma Corporation

VANCOUVER, British Columbia and WARMINSTER, Pa., March 12, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Wednesday, March 14, 2018 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss fourth quarter 2017 year-end financial … Continue reading Arbutus Announces Conference Call to Provide a Corporate Update and Fourth Quarter 2017 Year-End Financial Results

Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update

March 7, 2018
Xenon Pharmaceuticals Inc.

Two novel anti-epileptic drugs advancing in clinical development; Interim XEN1101 Phase 1 data expected to be released in May 2018 at scientific symposium; Xenon announces new clinical stage ion channel product to expand its neurology pipeline BURNABY, British Columbia, March 07, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today reported … Continue reading Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update

Aequus and EHave enter into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis

March 6, 2018
Aequus Pharmaceuticals Inc.

Ehave’s Bioinformatics Platform Technology to Be Used to Evaluate Aequus’ Products in Multiple Neurological Disorders VANCOUVER, BC. March 5, 2018 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (OTCQB: EHVVF) (“Ehave”), a healthcare bioinformatics … Continue reading Aequus and EHave enter into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2017 Financial Results and Provide Corporate Update

February 28, 2018
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Feb. 28, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2017 financial and operating results after the close of U.S. financial markets on Wednesday, March 7, 2018.  Xenon management will host a conference call and live audio webcast at 4:30 pm … Continue reading Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2017 Financial Results and Provide Corporate Update